Our Leadership

Carl Ross is the Managing Director of Waisman Biomanufacturing and is responsible for oversight of the highly trained staff and well-equipped facility. Mr. Ross has been with WB since its inception in 2001, participating in the design of GMP manufacturing, quality, and project management systems. Prior to assuming his current role, Mr. Ross served as a project manager and Manager of Process Development for WB, advancing a wide range of cell and gene therapies, vaccines, and therapeutic proteins into human clinical trials. Additionally, Mr. Ross spent over 10 years in industry developing and optimizing novel fermentation processes in the pharmaceutical, environmental, and agricultural sectors. Previous roles included serving as Fermentation Plant Manager at InterBio (The Woodlands, TX) and as Senior Process Scientist at Valentis/Gene Medicine (The Woodlands, TX). At Gene Medicine, he was primarily involved in the development and execution of fermentation and purification processes used in producing plasmid DNA for clinical applications. Mr. Ross received his B.S. in Microbiology from University of Illinois, Urbana-Champaign, and M.S. in Project Management from University of Wisconsin-Platteville. He also holds the PMP certification from the Project Management Institute and the RAC certification from the Regulatory Affairs Professionals Society.

John Welp is the Manager of Operations for Waisman Biomanufacturing.  Mr. Welp has a B.S. and an M.S. in Chemical Engineering from Rose-Hulman Institute of Technology and over 20 years of experience in industry developing manufacturing processes for biotherapeutics.  Mr. Welp previously served as the Director of Process Development at Powderject Vaccines (Madison, WI) and Director of Integrated Manufacturing at GeneMedicine Inc. (Woodlands, TX) where he was primarily involved in the development of manufacturing processes for DNA vaccines and plasmid DNA gene therapeutics.  Mr. Welp is primarily responsible for coordinating the activities of manufacturing personnel and ensuring that the equipment and facility are maintained, calibrated, validated and monitored according to WB Standard Operating Policies and cGMP guidelines.

Ross O. Meyers, Ph.D. is the Manager of Quality Control at Waisman Biomanufacturing.  Dr. Meyers has a Ph.D. from the University of Arizona, CALS and the Arizona Cancer Center Tucson, AZ.  His foundations of study are in Cancer Chemotherapeutics, Medicinal Chemistry and Pharmacology. His early research was at Rush University, Chicago, IL in protein structure-function studies and related mechanisms of arthritic cartilage damage. He joined the Arizona Cancer Center Therapeutic Development Program in 1993 where he researched chemotherapeutics; including pharmacokinetics, pharmacologic mechanism of action studies and related bioanalytical method development. He led a group of scientists in analytical R&D for the validation of biopharmaceutical methods at the PPD GMP labs, Madison, WI from 2006 to 2011. He joined Waisman Biomanufacturing in June of 2011. He leads a group supporting cGMP quantitative and qualitative QC testing and methods development for manufactured products.  The Quality Control group is responsible for the execution and management of in-house and out-sourced QC testing, documentation, data review and approval. The QC group manages and maintains cleanroom environmental monitoring.

John Vedo, is the Manager of Quality Assurance at Waisman Biomanufacturing.  Mr. Vedo has a B.S. in Biology from Indiana University and a M.B.A. from DePaul University.  Mr. Vedo has 20 years of experience in pharmaceutical and biotech cGMP environments.  Prior to assuming his current role, Mr. Vedo served as the Manager of Quality Assurance at Stratatech Corporation (Madison, WI) and before that as Manager of Quality and Finance at Networked Robotics Corporation (Evanston, IL).  Mr. Vedo began his career at Searle Pharmaceuticals (Skokie, IL) where he managed a storage and distribution facility for active pharmaceutical ingredients, as well as the site’s reference standard collection, discovery chemistry collection, and the site controlled substance file.   As Manager of Quality Assurance at WB, Mr. Vedo leads a team of quality professionals to ensure operational regulatory compliance with federal guidances as well as internal standard operating procedures. 

Brian Dattilo, Ph.D. is the Manager of Business Development at Waisman Biomanufacturing. Dr. Dattilo received his Ph.D. in Biochemistry from Vanderbilt University where he focused on recombinant protein production, purification, and analytical characterization. Prior to Waisman Dr. Dattilo was in public service serving as a Program Manager at the Biomedical Advanced Research and Development Authority (BARDA), where he was responsible for a multi-million dollar development budget supporting novel platform technologies and their application to vaccine, biological therapeutic, and diagnostic development for pandemic influenza and biodefense applications.  Since joining WB in 2012 he has led client interaction, technical product development plan development, project budgeting and cost estimation, and built business cases for new platform investment.